Barry S. Coller, MD, is vice president for medical affairs, David Rockefeller Professor, head of the Allen and Frances Adler Laboratory of Blood and Vascular Biology, and physician-in-chief at The Rockefeller University. He is an expert on the basic molecular mechanisms involved in blood clotting and thrombosis. His research accomplishments include the development of a monoclonal antibody to platelets that was developed into the drug ReoPro. He is also the inventor of RUC-4.

Robert S. Hillman, PhD, is a biomedical engineer and successful serial entrepreneur/inventor. He studied at Stanford University, MIT, and the Swiss Federal Institute of Technology (ETH-Z). Early in his career, Dr. Hillman led the development of the GenESA System, the first drug-device combination cleared by the FDA for diagnosing coronary artery disease. Dr. Hillman was also co-founder at Accumetrics, where he led the development of the VerifyNow System; Biotrack, where he lead the development of the CoaguCheck System; Tem Systems, where he led the development of the Rotem Sigma; and ActivX Biosciences, an early pioneer in activity-based proteomics. Many of these products are still in use today in hospitals and research institutions worldwide.

Andreas Ritzi is CFO of Cadorit AG, a Swiss-based investment company. He is a financial specialist and accomplished entrepreneur. He has an MBA from the University of St. Gallen and an MSc in Finance from the London Business School.

Jack Lief co-founded Arena Pharmaceuticals, Inc. and served as its president and chief executive officer. He served as chairman of the board of directors of BIOCOM and is an executive board member of BIOCOM. He also held senior business development positions at Cephalon, Alpha Therapeutics and Abbott Laboratories.